Peptide market reaches $50B to $60B as GLP-1 drugs drive growth

The Peptide Alliance says the global peptide market is now worth $50 billion to $60 billion, with about $40 billion tied to GLP-1 drugs like semaglutide and tirzepatide. The report also highlights a shrinking compounded-semaglutide market, advancing retatrutide trials and new rankings of top peptide influencers and conferences.

Why it matters: - The peptide market is moving from a niche category to a mainstream health care and consumer market. - GLP-1 drugs are now driving most of the market’s value, which raises the stakes for suppliers, clinics, compounding pharmacies and investors. - The report suggests the industry is consolidating around verified products and legitimate channels.

What happened: - The Peptide Alliance released The State of Peptides 2026 (H1 Edition) on July 22, 2026. - The report estimates the global peptide market at $50 billion to $60 billion. - The report says about $40 billion of that market is now driven by GLP-1 drugs such as semaglutide and tirzepatide. - The Peptide Alliance also published ranked indexes of the industry’s top influencers and top conferences. - The full report is available free here.

The details: - The report says an estimated 1 in 8 U.S. adults has used a GLP-1 medication. - The report says the compounded-semaglutide market contracted about 90% year over year after regulatory changes. - The report says retatrutide advanced through Phase 3 after trials showed roughly 24.2% mean body-weight reduction. - The Top Peptide Influencers ranking covers voices across media, clinical medicine and research. - The Top Peptide Conferences ranking is led by TIDES USA, the A4M/MMI Annual World Congress and the Peptide World Congress. - Both rankings use a published, weighted methodology. - The rankings draw on a verified directory of 306 active suppliers. - The directory includes clinics, compounding pharmacies, brands, research labs and manufacturers.

Between the lines: - The report reflects a market where GLP-1 demand is reshaping pricing power, distribution and public attention. - The sharp drop in compounded semaglutide points to regulatory pressure changing where patients and prescribers turn. - The emphasis on verified suppliers and reviewed rankings signals an effort to separate established players from the wider peptide boom. - The rapid rise in market size also suggests data quality and trust are becoming competitive advantages.

What's next: - The Peptide Alliance will continue publishing its biannual State of Peptides report. - The organization will maintain its ranked indexes of peptide influencers, conferences and suppliers. - Retatrutide’s Phase 3 progress will remain a key development to watch in the next wave of peptide drugs. - The market will likely keep shifting as regulators, drugmakers and compounders respond to GLP-1 demand.

The bottom line: - Peptides are no longer just an emerging category. GLP-1 drugs have turned the market into a multibillion-dollar race for legitimacy, supply and influence.